8 Works
Project Supplementary Materials from No strong evidence for universal gender differences in the development of cooperative behaviour across societies
Bailey House, Joan B. Silk & Katherine McAuliffe
File contains all code for running regression models, all data used in these models, and full numerical results for all models.
Project Supplementary Materials from No strong evidence for universal gender differences in the development of cooperative behaviour across societies
Bailey House, Joan B. Silk & Katherine McAuliffe
File contains all code for running regression models, all data used in these models, and full numerical results for all models.
Additional file 1 of Race-related differences in the economic, healthcare-access, and psychological impact of COVID-19: personal resources associated with resilience
Carolyn E. Schwartz, Katrina Borowiec, Elijah Biletch & Bruce D. Rapkin
Additional file 1. Table S1. COVID-Specific Items and Scales. Table S2. Descriptive Statistics of Person-Reported Outcomes. Table S3. Unadjusted Group Comparisons on Person-Reported Outcomes. Table S4. Representativeness Checks. Table S5. Distribution of Covariates in the Matched Samples. Table S6. Comparison of Explained Variance by Demographics and COVID-specific Variables in Whole-Sample vs. Matched Cohort Analyses.
Revisions to the Young Schema Questionnaire using Rasch analysis: the YSQ-R
Ozgur Yalcin, Ida Marais, Christopher Lee & Helen Correia
The aim of this study was to refine the YSQ-L3 by identifying the most statistically and clinically appropriate items for each Early Maladaptive Schema (EMS) using Rasch analysis. A Rasch analysis was undertaken on a large sample (N = 838) that included a heterogeneous clinical sample (N = 574) and a smaller non-clinical group (N = 264). Overall, 116 out of 232 items showed misfit across a number of statistical indicators. After the removal of...
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Rontgene Solante, Carlos Alvarez-Moreno, Erlina Burhan, Suwat Chariyalertsak, Nan-Chang Chiu, Sunate Chuenkitmongkol, D. V. Dung, Kao-Pin Hwang, Javier Ortiz Ibarra, Sasisopin Kiertiburanakul, Prasad S. Kulkarni, Christopher Lee, Ping-Ing Lee, Rommel Crisenio Lobo, Alejandro Macias, Cao Huu Nghia, Anna Lisa Ong-Lim, Alfonso J. Rodriguez-Morales, Rosana Richtmann, Marco Aurélio Palazzi Safadi, Hindra Irawan Satari & Guy Thwaites
COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death...
Additional file 1 of Race-related differences in the economic, healthcare-access, and psychological impact of COVID-19: personal resources associated with resilience
Carolyn E. Schwartz, Katrina Borowiec, Elijah Biletch & Bruce D. Rapkin
Additional file 1. Table S1. COVID-Specific Items and Scales. Table S2. Descriptive Statistics of Person-Reported Outcomes. Table S3. Unadjusted Group Comparisons on Person-Reported Outcomes. Table S4. Representativeness Checks. Table S5. Distribution of Covariates in the Matched Samples. Table S6. Comparison of Explained Variance by Demographics and COVID-specific Variables in Whole-Sample vs. Matched Cohort Analyses.
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Rontgene Solante, Carlos Alvarez-Moreno, Erlina Burhan, Suwat Chariyalertsak, Nan-Chang Chiu, Sunate Chuenkitmongkol, D. V. Dung, Kao-Pin Hwang, Javier Ortiz Ibarra, Sasisopin Kiertiburanakul, Prasad S. Kulkarni, Christopher Lee, Ping-Ing Lee, Rommel Crisenio Lobo, Alejandro Macias, Cao Huu Nghia, Anna Lisa Ong-Lim, Alfonso J. Rodriguez-Morales, Rosana Richtmann, Marco Aurélio Palazzi Safadi, Hindra Irawan Satari & Guy Thwaites
COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death...
Revisions to the Young Schema Questionnaire using Rasch analysis: the YSQ-R
Ozgur Yalcin, Ida Marais, Christopher Lee & Helen Correia
The aim of this study was to refine the YSQ-L3 by identifying the most statistically and clinically appropriate items for each Early Maladaptive Schema (EMS) using Rasch analysis. A Rasch analysis was undertaken on a large sample (N = 838) that included a heterogeneous clinical sample (N = 574) and a smaller non-clinical group (N = 264). Overall, 116 out of 232 items showed misfit across a number of statistical indicators. After the removal of...